Last updated: September 8, 2026
Anagrelide hydrochloride is a mature, low-cost generic drug used primarily to reduce platelet counts in adults with essential thrombocythemia and other myeloproliferative neoplasms. Its U.S. market has moved from branded Agrylin exclusivity to commodity-style generic competition. Patent and regulatory barriers are limited, biosimilar risk is irrelevant, and financial growth depends mainly on diagnosis rates, treatment-line positioning, supply continuity, and generic pricing rather than innovation.
What is the current market position of anagrelide hydrochloride?
Anagrelide hydrochloride is a platelet-reducing agent supplied mainly as oral capsules. It inhibits megakaryocyte maturation and lowers platelet production. The FDA approved Agrylin, the reference brand, in 1997 for the treatment of thrombocythemia associated with myeloproliferative disorders [1].
The drug occupies a specialized position in hematology:
| Market factor |
Current position |
| Primary use |
Essential thrombocythemia and related myeloproliferative neoplasms |
| Dosage form |
Immediate-release oral capsules |
| Common strengths |
0.5 mg and 1 mg capsules |
| Market type |
Mature generic prescription market |
| U.S. reference brand |
Agrylin |
| FDA approval |
1997 |
| Current innovation barrier |
Low |
| Biosimilar exposure |
None |
| Main competitors |
Hydroxyurea, peginterferon alfa, aspirin, ruxolitinib in selected settings |
| Commercial value driver |
Chronic treated-patient volume and generic supply reliability |
Anagrelide is generally used when platelet reduction is required and hydroxyurea is unsuitable, poorly tolerated, or clinically undesirable. European treatment algorithms also position it as a second-line or alternative cytoreductive therapy in selected essential thrombocythemia patients [2].
When does anagrelide hydrochloride lose exclusivity?
U.S. market exclusivity for anagrelide hydrochloride has already expired. The original Agrylin approval dates to 1997, and the product no longer benefits from meaningful regulatory exclusivity or enforceable blocking patent protection in the U.S. generic market [1,3].
Exclusivity timeline
| Event |
Approximate date |
Commercial effect |
| Agrylin approved by FDA |
1997 |
Originator launch |
| Brand commercial period |
Late 1990s to early 2010s |
Protected branded market |
| Generic entry |
Mid-2010s |
Price competition begins |
| Current status |
Mature generic market |
Low barriers to additional suppliers |
The key economic transition occurred when generic manufacturers obtained abbreviated new drug application approvals. Generic products could rely on the reference drug’s safety and efficacy findings while demonstrating pharmaceutical equivalence and bioequivalence under the ANDA pathway [4].
What patents protect anagrelide hydrochloride?
The historical patent estate covered the anagrelide compound and related pharmaceutical uses. Those rights are no longer a material barrier to U.S. generic entry.
The relevant protection categories were:
- Compound patents covering anagrelide and related chemical structures.
- Pharmaceutical composition claims covering oral capsule formulations.
- Method-of-use claims involving platelet reduction and thrombocythemia.
- Manufacturing and formulation claims associated with the active ingredient and dosage form.
The practical U.S. position is more important than the historical patent chronology: the Orange Book does not present an active patent barrier that prevents routine generic supply of anagrelide hydrochloride capsules [3].
What is the Orange Book status of anagrelide hydrochloride?
The FDA Orange Book identifies the reference product and approved generic equivalents. Anagrelide hydrochloride capsules are treated as a conventional small-molecule generic product, not as a biologic requiring biosimilar approval [3].
There is no current commercial rationale for a Paragraph IV campaign comparable to those associated with high-value branded medicines. The principal patent expiry events occurred before the present generic market structure developed.
Are there Paragraph IV challenges or patent litigation involving anagrelide?
Anagrelide hydrochloride has no widely reported active U.S. patent litigation that materially affects market access. The product’s low sales value and expired core protection reduce the economic incentive for a major Paragraph IV dispute.
Paragraph IV risk
A Paragraph IV certification alleges that a listed patent is invalid, unenforceable, or not infringed. For anagrelide hydrochloride, the commercial case for such litigation is weak because:
- The principal compound protection is old.
- Generic products are already marketed.
- No significant new formulation franchise has established a high-value patent barrier.
- Expected litigation damages would be limited by the drug’s low annual market value.
- Generic manufacturers can compete through routine ANDA filings.
There may be ordinary product liability, manufacturing, quality, or supply disputes, but those are distinct from patent litigation and do not create durable market exclusivity.
What formulations are protected by anagrelide patents?
The commercial product is an immediate-release oral capsule. The market does not currently depend on a novel extended-release, long-acting, injectable, transdermal, or depot formulation.
Historical and regulatory formulation protection has generally focused on:
- Capsule dosage forms.
- Anagrelide hydrochloride as the active pharmaceutical ingredient.
- Strengths of 0.5 mg and 1 mg.
- Pharmaceutical excipients and dissolution characteristics.
- Manufacturing specifications supporting bioequivalence.
Because the active product is an established immediate-release capsule, formulation differentiation is limited. A manufacturer could seek protection for a new delivery system, but a successful product would need to demonstrate clinically meaningful advantages such as improved tolerability, reduced dosing frequency, lower cardiovascular toxicity, or better adherence.
No such reformulated franchise has displaced the standard capsule in the U.S. market.
How strong is the patent estate for anagrelide hydrochloride?
The current patent estate is weak from a market-exclusion perspective.
| Patent-estate category |
Assessment |
| Core compound protection |
Expired or commercially exhausted |
| Method-of-use protection |
No meaningful current barrier to generic capsule sales |
| Formulation protection |
Limited commercial significance |
| Manufacturing protection |
May protect processes privately, but does not block standard generic entry |
| Orange Book exclusivity |
No material current barrier |
| Litigation leverage |
Low |
| Licensing value |
Low unless tied to a novel formulation or geographic market |
Manufacturing know-how can still have value. Suppliers must control impurity profiles, polymorph or solid-state characteristics, process reproducibility, and stability. These factors may create operational advantages without producing legally enforceable market exclusivity.
What is the FDA regulatory status of anagrelide hydrochloride?
FDA-approved anagrelide hydrochloride capsules are regulated as prescription drugs under the ANDA and NDA frameworks. The approved label includes warnings related to cardiovascular effects, including tachycardia, palpitations, arrhythmias, and heart failure risk. The drug also has gastrointestinal and hematologic safety considerations [5].
The FDA label requires careful dosing and monitoring. Anagrelide is not a simple over-the-counter platelet-lowering product, even though the active ingredient is generic.
Key regulatory factors include:
- Bioequivalence to the reference product.
- Consistent capsule dissolution and strength.
- Control of active pharmaceutical ingredient impurities.
- Manufacturing compliance under current good manufacturing practices.
- Pharmacovigilance for cardiovascular and bleeding events.
- Label consistency across generic manufacturers.
The regulatory pathway is established, but FDA inspection findings, manufacturing interruptions, or quality-control failures can affect supply.
How does anagrelide compare with competing cytoreductive drugs?
Anagrelide competes mainly on clinical positioning rather than brand marketing.
| Drug or class |
Main commercial role |
Competitive relationship |
| Hydroxyurea |
Common first-line cytoreduction |
Strongest practical substitute in many patients |
| Peginterferon alfa |
Cytoreduction, including selected younger patients |
Competes where long-term disease control is prioritized |
| Aspirin |
Thrombosis prevention, not equivalent platelet cytoreduction |
Complementary rather than direct substitute |
| Ruxolitinib |
Selected myelofibrosis and related disease settings |
Higher-value targeted therapy; narrower overlap |
| Anagrelide |
Platelet-focused cytoreduction |
Alternative or second-line option |
European LeukemiaNet recommendations emphasize risk-adapted treatment for essential thrombocythemia. The choice between hydroxyurea, interferon, and anagrelide depends on age, thrombosis history, disease risk, pregnancy considerations, tolerability, and cardiovascular status [2].
Anagrelide’s principal commercial disadvantage is that it does not generally command specialty-drug pricing despite serving a specialist population. Its principal advantage is that it provides an oral non-chemotherapy alternative when hydroxyurea is unsuitable.
What is the financial trajectory for anagrelide hydrochloride?
The financial trajectory is best described as a decline from branded sales followed by a stable, low-value generic phase.
Public company filings generally do not disclose anagrelide hydrochloride revenue as a standalone product line. Manufacturers report generic portfolios at broader business-unit levels, preventing a reliable public calculation of product-specific revenue or profit [6,7].
Revenue trajectory
| Period |
Financial pattern |
| Branded launch and expansion |
Higher unit price and concentrated supplier economics |
| Generic entry |
Rapid price erosion and share fragmentation |
| Mature generic phase |
Lower prices, stable clinical demand, limited margin |
| Long-term outlook |
Low-single-digit volume growth at best, with periodic price and supply volatility |
The product’s total market value is constrained by several factors:
- Essential thrombocythemia is a relatively small patient population.
- Treatment is chronic, but patient numbers are limited.
- Generic competition suppresses net pricing.
- Prescribers have several cytoreductive alternatives.
- Manufacturers do not normally invest heavily in promotion.
- Reimbursement is generally established for FDA-approved generic products.
Revenue can still be meaningful for a manufacturer with low production costs and efficient distribution. It is unlikely to materially affect the consolidated financial results of a large diversified pharmaceutical company.
Which companies are competing in the anagrelide market?
Competition consists primarily of generic manufacturers and contract suppliers. The market has included large generic companies and regional suppliers with FDA-approved or globally registered products. Public product listings and DailyMed records identify multiple manufacturers or labelers over time [5].
Competitive differentiation is based on:
- Reliable API procurement.
- FDA-compliant manufacturing.
- Wholesale acquisition cost and contract pricing.
- Supply continuity.
- National distribution coverage.
- Ability to maintain both 0.5 mg and 1 mg presentations.
- Low product-return and shortage risk.
The reference brand has limited strategic power after generic substitution. A generic supplier with a dependable supply chain can gain share even without a differentiated clinical profile.
What generic entry risks exist?
Generic entry risk is already realized rather than prospective. The remaining commercial risks concern price, supply, and product substitution.
Principal risks
- Price erosion: Additional suppliers can reduce contract prices and gross margin.
- Channel concentration: Dependence on a small number of wholesalers or group purchasing organizations can weaken pricing.
- API disruption: A manufacturing issue at one API source can interrupt finished-dose production.
- Regulatory action: FDA warning letters, import alerts, or recalls can remove a supplier from the market.
- Clinical substitution: Physicians may choose hydroxyurea or interferon instead.
- Hospital and specialty-pharmacy purchasing pressure: Buyers can shift volume to the lowest-cost approved source.
The market is more exposed to manufacturing risk than to patent risk.
Is there biosimilar risk for anagrelide hydrochloride?
No. Anagrelide hydrochloride is a synthetic small molecule, not a biologic. Biosimilar competition is therefore irrelevant.
The relevant substitute is an ANDA-approved generic equivalent. A biosimilar pathway would not apply to the capsule product, and there is no biologic version of anagrelide hydrochloride competing in the market.
What licensing deals affect anagrelide hydrochloride?
Anagrelide has had commercial rights transfers and brand ownership changes during its product history, but the mature generic market is not dependent on a major current licensing arrangement.
The most important commercial relationship is between:
- API manufacturers,
- finished-dose generic manufacturers,
- contract manufacturing organizations,
- wholesalers,
- specialty distributors, and
- institutional purchasers.
A new licensing deal would have meaningful value only if it involved one of the following:
- A differentiated extended-release formulation.
- A new indication with strong clinical adoption.
- A proprietary manufacturing process that materially reduces cost.
- Exclusive rights in a major emerging market.
- A combination product with a clinically validated advantage.
Absent such developments, licensing economics are limited by low generic pricing.
What is the geographic coverage of anagrelide hydrochloride?
Anagrelide is marketed in the United States and multiple international markets, often under the Agrylin, Xagrid, or generic anagrelide names. Regulatory status and reimbursement differ by country.
The European market has historically been important because essential thrombocythemia treatment algorithms recognize anagrelide as an established cytoreductive option. In some jurisdictions, the product has been supplied under a brand or hospital-oriented model rather than a fully commoditized retail-generic model.
Geographic commercial performance depends on:
- National reimbursement decisions.
- Generic substitution rules.
- Local patent expiry.
- Tender purchasing.
- Presence of local manufacturers.
- Essential-medicine or shortage policies.
- Availability of hydroxyurea and interferon alternatives.
The United States is a mature generic market. Europe and selected emerging markets may offer modest growth through wider diagnosis and treatment access, but the product is unlikely to become a high-growth pharmaceutical asset.
What patent litigation and settlement agreements affect the market?
No major current U.S. settlement agreement appears to control generic entry for anagrelide hydrochloride. Because generic products are already available, any historical patent disputes would have limited present-day commercial relevance.
The absence of a major settlement structure means:
- No delayed generic launch agreement is central to the market.
- No authorized-generic strategy controls broad U.S. supply.
- No active patent cliff remains to produce a sudden wave of entrants.
- Market share is determined primarily by manufacturing and contracting.
Key Takeaways
- Anagrelide hydrochloride is a mature oral generic used mainly for essential thrombocythemia.
- U.S. exclusivity has expired, and the Orange Book does not present a material current patent barrier.
- The product has no biosimilar risk because it is a small molecule.
- Generic competition has reduced pricing and shifted value from intellectual property to manufacturing reliability.
- Hydroxyurea and peginterferon alfa are the main clinical alternatives.
- Public filings do not generally disclose standalone anagrelide revenue.
- The financial outlook is stable but low-growth, with limited upside absent a new formulation or indication.
- Supply interruptions, quality events, and contract pricing are greater risks than patent litigation.
- The product can remain profitable for efficient generic suppliers but is unlikely to materially affect a large pharmaceutical company’s consolidated revenue.
FAQs
Is anagrelide hydrochloride still commercially viable?
Yes, but mainly as a low-cost specialty generic. Commercial viability depends on efficient manufacturing, stable API supply, and access to hematology and pharmacy distribution channels.
Does anagrelide hydrochloride have orphan-drug pricing power?
No. Its use in a relatively uncommon disease does not create current orphan-drug pricing power because the product is old, generic, and clinically replaceable.
Can a new company launch an anagrelide generic?
In principle, a manufacturer can enter through the ANDA pathway if it satisfies FDA requirements for bioequivalence, quality, manufacturing, labeling, and supply. Commercial success would depend on pricing and distribution rather than patent differentiation.
Is anagrelide more commercially attractive than hydroxyurea?
Usually not. Hydroxyurea has broader use and a larger established treatment base. Anagrelide can be attractive as a niche product when clinical guidelines or patient tolerability favor platelet-specific therapy.
Could an extended-release anagrelide product create a new franchise?
Potentially. A differentiated product would need credible evidence of improved adherence, tolerability, cardiovascular safety, or clinical outcomes. Without a meaningful clinical advantage, an extended-release version would face reimbursement and substitution pressure.
References
-
U.S. Food and Drug Administration. (1997). Agrylin (anagrelide hydrochloride) prescribing information. FDA.
-
Barbui, T., Tefferi, A., Vannucchi, A. M., Passamonti, F., Silver, R. T., Hoffman, R., et al. (2018). Philadelphia chromosome-negative classical myeloproliferative neoplasms: Critical concepts and management recommendations from European LeukemiaNet. Journal of Clinical Oncology, 36(2), 181-194.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Food and Drug Administration. (2024). Abbreviated new drug application (ANDA) process. FDA.
-
National Library of Medicine. (2024). DailyMed: Anagrelide hydrochloride capsule labeling. U.S. National Library of Medicine.
-
Teva Pharmaceutical Industries Ltd. (2024). Annual report 2023. Teva.
-
Viatris Inc. (2024). Annual report 2023. Viatris.
